Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities (2021)
Amylyx Pharmaceuticals (AMLX) posted Preferred Stock Liabilities of $239.4 million for Q4 2021, up 77.57% on a QoQ basis from $134.8 million in Q3 2021.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities (2021) Analysis & Trends
Amylyx Pharmaceuticals has reported Preferred Stock Liabilities for 1 years, with the latest figure at $239.4 million in Q4 2021.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $239.4 million in Q4 2021; TTM through Dec 2021 was $239.4 million, a N/A change from a year earlier, with the FY2021 full-year figure at $239.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $239.4 million for Q4 2021 at Amylyx Pharmaceuticals, up from $134.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $239.4 million in Q4 2021, with the low at $64.4 million in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | - |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 239.35 Mn |
| Sep 30, 2021 | 134.79 Mn |
| Jun 30, 2021 | 64.39 Mn |
| Mar 31, 2021 | 64.39 Mn |